Department of Internal Medicine, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Ciber Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Nutrients. 2020 Oct 22;12(11):3227. doi: 10.3390/nu12113227.
The "legacy effect" describes the long-term benefits that may persist for many years after the end of an intervention period, involving different biological processes. The legacy effect in cardiovascular disease (CVD) prevention has been evaluated by a limited number of studies, mostly based on pharmacological interventions, while few manuscripts on dietary interventions have been published. Most of these studies are focused on intensive treatment regimens, whose main goal is to achieve tight control of one or more cardiovascular risk factors. This review aims to summarise the legacy effect-related results obtained in those studies and to determine the existence of this effect in CVD prevention. There is sufficient data to suggest the existence of a legacy effect after intensive intervention on cardiovascular risk factors; however, this effect is not equivalent for all risk factors and could be influenced by patient characteristics, disease duration, and the type of intervention performed. Currently, available evidence suggests that the legacy effect is greater in subjects with moderately-high cardiovascular risk but without CVD, especially in those patients with recent-onset diabetes. However, preventive treatment for CVD should not be discontinued in high-risk subjects, as the level of existing evidence on the legacy effect is low to moderate.
“遗留效应”描述了干预期结束后可能持续多年的长期益处,涉及不同的生物学过程。心血管疾病(CVD)预防中的遗留效应已经通过少数研究进行了评估,这些研究大多基于药物干预,而关于饮食干预的研究论文则很少发表。这些研究大多集中在强化治疗方案上,其主要目标是实现对一个或多个心血管风险因素的严格控制。本综述旨在总结这些研究中获得的与遗留效应相关的结果,并确定其在 CVD 预防中的存在。有充分的数据表明,在对心血管风险因素进行强化干预后存在遗留效应;然而,这种效应并不是对所有风险因素都等效的,并且可能受到患者特征、疾病持续时间和所进行的干预类型的影响。目前,现有证据表明,在没有 CVD 但具有中高度心血管风险的患者中,遗留效应更大,尤其是在近期发病的糖尿病患者中。然而,不应该停止对高危患者的 CVD 预防治疗,因为遗留效应的现有证据水平较低。